Walleye Capital LLC Purchases Shares of 1,121,738 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Walleye Capital LLC purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,121,738 shares of the company's stock, valued at approximately $3,197,000. Walleye Capital LLC owned approximately 0.75% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in XERS. Simplicity Wealth LLC purchased a new stake in Xeris Biopharma in the 2nd quarter worth approximately $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma in the 3rd quarter worth approximately $35,000. Allspring Global Investments Holdings LLC lifted its position in Xeris Biopharma by 4,512.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company's stock worth $37,000 after buying an additional 15,929 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Xeris Biopharma in the 3rd quarter worth approximately $44,000. Finally, Asset Management Group Inc. lifted its position in Xeris Biopharma by 130.7% in the 2nd quarter. Asset Management Group Inc. now owns 26,480 shares of the company's stock worth $60,000 after buying an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

NASDAQ:XERS traded up $0.04 during midday trading on Tuesday, reaching $3.42. The stock had a trading volume of 3,633,454 shares, compared to its average volume of 1,716,979. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.64. The firm's fifty day simple moving average is $3.08 and its 200-day simple moving average is $2.65.

Analyst Ratings Changes

A number of equities research analysts have issued reports on XERS shares. Piper Sandler downgraded shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a research report on Monday, November 11th. HC Wainwright increased their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a "buy" rating in a research report on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.